Status:

UNKNOWN

Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS

Lead Sponsor:

Hospital Universitari Vall d'Hebron Research Institute

Conditions:

COVID

ARDS

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Prone position (PP) has been proved to be effective in severe ARDS patients. On the other hand, High flow nasal cannula (HFNC) may prevent intubation in hypoxemic Acute respiratory failure (ARF) patie...

Eligibility Criteria

Inclusion

  • COVID-19 pneumonia according to the diagnostic criteria in effect at the time of inclusion or very strongly suspected.
  • Patient treated by nasal high flow.
  • Moderate or severe ARDS: bilateral radiological opacities not explained entirely by effusions, atelectasis or nodules; acute hypoxemia with worsening within the 7 previous days, not entirely explained by left ventricular failure; PaO2 / FiO2 ratio \<300 mmHg (or SpO2 / FiO2 equivalent).
  • Informed consent.
  • Beneficiary or affiliated to a social security scheme.

Exclusion

  • Indication of immediate tracheal intubation
  • Significant acute progressive circulatory insufficiency
  • Impaired alertness, confusion, restlessness
  • Body mass index\> 40 kg / m2
  • Chest trauma or other contraindication to prone position
  • Pneumothorax
  • Vulnerable person: safeguard of justice
  • Pregnant or lactating woman

Key Trial Info

Start Date :

May 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2021

Estimated Enrollment :

248 Patients enrolled

Trial Details

Trial ID

NCT04391140

Start Date

May 13 2020

End Date

June 1 2021

Last Update

August 18 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitari Vall d'Hebron

Barcelona, Spain, 08035